Sustained dengue transmission and seroprevalence in the U.S. Virgin Islands

A cross-sectional study in the U.S. Virgin Islands found that nearly half of children aged 8–16 have been previously infected with dengue virus, yet parental awareness and acceptance of dengue vaccination remain critically low.

The Gist

The "Invisible Guest" in the US Virgin Islands: A Summary

Imagine you are hosting a massive, year-round party in your house. Most of the time, it’s quiet. But every once in a while, a group of uninvited guests—let's call them the "Dengue Crew"—bursts in, makes a huge mess, and leaves. Because many of these guests are quiet and sneaky, you might not even realize they were there until the house is already a wreck.

A recent scientific study looked at exactly this situation in the U.S. Virgin Islands (USVI), focusing on children. Here is the breakdown of what they found, using a few simple metaphors.

---

1. The "Silent Invaders" (High Seroprevalence)

The researchers went to schools to check if children had ever been infected with the dengue virus. They found something startling: nearly half (47%) of the children had already been "visited" by the virus.

The Analogy: Think of it like a "silent alarm." Most parents thought their children were safe because they hadn't seen any obvious signs of trouble (like a high fever or a hospital visit). However, the blood tests acted like a security camera that caught the intruders in the act. It turns out the virus is a master of disguise—it often enters the body so quietly (asymptomatic) that parents never even know it happened.

2. The "Rollercoaster" of Infection (Force of Infection)

The study didn't just look at who was infected; it looked at when the virus was most active. They found that dengue doesn't just trickle in; it comes in massive waves. Specifically, there were huge "spikes" during the 2012–2013 outbreaks.

The Analogy: Transmission in the USVI is like a rollercoaster. Most of the time, the ride is slow and low to the ground (low transmission). But every few years, the tracks shoot straight up into a massive, scary loop (an outbreak). During those peak years, the risk of catching the virus jumps significantly.

3. The "Empty Toolbox" (Vaccine Awareness)

The researchers also asked parents about vaccines. This is where they found a major problem. Even though the virus is common, very few parents knew that a dengue vaccine even existed.

The Analogy: Imagine you live in a neighborhood where it rains heavily every few years, but most people don't own an umbrella and don't even know umbrellas are for sale. When the storm finally hits, everyone gets soaked. The study found that while the "rain" (dengue) is a known part of life in the USVI, the "umbrellas" (vaccines) are currently missing from most people's mental toolkits.

---

The Big Picture: What does this mean?

The researchers are sending a "flare" up to public health officials. They are saying:

• We need better "Security Cameras": Since many infections are silent, we need better ways to detect the virus before it turns into a massive outbreak.
• We need to hand out "Umbrellas": If a vaccine becomes widely available, we can't just leave it on the shelf. We need to educate parents so they are ready and willing to protect their kids.
• Targeted Protection: Some groups (like certain neighborhoods or specific age groups) seem to be hit harder by the "guests." We need to make sure those people get the most help and information.

In short: The virus is more common than people realize, it moves in unpredictable waves, and we need to get better at preparing the community before the next big wave hits.

Technical Summary

Technical Summary: Sustained Dengue Transmission and Seroprevalence in the U.S. Virgin Islands

Problem Statement

Dengue virus (DENV) is a major global arboviral threat, with incidence doubling between 1990 and 2021. In the U.S. Virgin Islands (USVI), dengue is endemic, characterized by periodic outbreaks and a disproportionate impact on children and adolescents. Despite this, there has been a lack of formal, population-based serosurveys to quantify the actual burden of infection. This lack of data hinders public health preparedness, complicates the planning of vector management, and creates uncertainty regarding the implementation of dengue vaccination strategies, which require accurate knowledge of prior infection status to ensure safety and efficacy.

Methodology

The researchers employed a multi-faceted approach combining serological testing, catalytic modeling, and behavioral surveys:

• Study Design & Sampling: A cross-sectional serosurvey was conducted in April–May 2022 among 372 children (ages 8–16) across 15 schools in the USVI. The study used a single-stage cluster sampling design, stratified by health districts (St. Croix and St. Thomas/St. John), with weights adjusted via raking to match 2022 US Census distributions.
• Laboratory Testing: Prior DENV infection was assessed using the CTK Biotech OnSite Dengue IgG Rapid Test (sensitivity 89.6%, specificity 95.7%) via fingerstick whole blood samples.
• Catalytic Modeling: To estimate the annual Force of Infection (FOI)—the rate at which seronegative individuals become infected—the team used Bayesian Markov chain Monte Carlo (MCMC) methods in RStan. The model integrated individual-level seropositivity data with longitudinal surveillance case data from the National Arbovirus Surveillance System (ArboNET) spanning 2010–2022.
• Behavioral Assessment: A parental questionnaire was administered to assess demographics, dengue knowledge, and vaccine acceptability (using vector generalized linear models to analyze responses).

Key Contributions

1. First Representative Serosurvey: Provided the first large-scale estimate of DENV seroprevalence among school-aged children in the USVI.
2. Transmission Dynamics Mapping: Quantified the historical "Force of Infection," distinguishing between high-transmission outbreak years and low-transmission inter-epidemic periods.
3. Vaccine Readiness Assessment: Identified a critical gap between biological risk (high seroprevalence) and community preparedness (low vaccine awareness).

Results

• Seroprevalence: The overall weighted seroprevalence among children aged 8–13 was 47% (95% CI: 29%, 68%). Seroprevalence increased with age (27% in 8-year-olds vs. 69% in 12-year-olds) and was higher in the St. Thomas/St. John district (59%) than in St. Croix (34%).
• Transmission Patterns: The FOI peaked during the 2012–2013 outbreaks (15%–18% annual incidence among seronegative children). In non-outbreak years, the FOI remained <1%. The study also noted a low reporting fraction (as low as 1.6% in some areas), suggesting massive underreporting of asymptomatic or mild cases.
• Risk Factors: Higher infection hazards were associated with being female, Hispanic, or of Asian/Pacific Islander descent.
• Vaccine Perceptions: There was a significant disconnect in awareness: while nearly half of the children had been infected, 84% of parents believed their child had never had dengue, and only 17% were aware of an approved dengue vaccine. Only 25% of parents expressed a willingness to vaccinate their child.

Significance and Policy Implications

The study reveals a "silent" burden of dengue in the USVI, where high levels of infection go unrecognized by caregivers. This has profound implications for public health:

• Vaccination Strategy: Because current vaccines (like Dengvaxia) require prior infection confirmation for safe administration, the high seroprevalence suggests the target population is large, but the low parental awareness poses a significant barrier to uptake.
• Surveillance & Diagnostics: The discrepancy between seroprevalence and reported cases underscores the need for enhanced diagnostic capacity and improved clinical suspicion to capture the true extent of transmission.
• Public Health Intervention: The findings advocate for targeted educational campaigns, particularly for long-term residents and those with low prior dengue awareness, to prepare the community for the introduction of new vaccines (e.g., Qdenga).